Research and Clinical Trials

Brief Description  
LCCC 1025 is a trial evaluating the efficacy and tolerability of everolimus (RAD001) in combination with trastuzumab and vinorelbine in HER2 positive breast cancer patients with at least one progressive and/or new metastatic brain lesion after receipt of intracranial radiation therapy. Patients will take oral everolimus daily, and trastuzumab + vinorelbine IV weekly, until progression of disease, unacceptable toxicities, or by the choice of the patient or doctor.
Who may be Eligible  
HER2 positive breast cancer Women and men Brain metastasis No limit to prior therapies Must have had prior intracranial radiation therapy (whole brain radiation therapy, stereotactic radiosurgery, gamma knife, or equivalent)
IRB Number  
Principal Investigator  
Limentani, Steven

For More Information, Contact  Kate  I, Ormont
Phone:  (704) 355-8298  Fax:  (704) 355-0000  
Address:1100 S. Tryon Street Suite 220 Charlotte, NC 28203